135 related articles for article (PubMed ID: 34058473)
1. Combined use of cisplatin plus natural killer cells overcomes immunoresistance of cisplatin resistant ovarian cancer.
Choi SH; Jung D; Kim KY; An HJ; Park KS
Biochem Biophys Res Commun; 2021 Jul; 563():40-46. PubMed ID: 34058473
[TBL] [Abstract][Full Text] [Related]
2. Rapamycin enhanced the antitumor efficacy of oxaliplatin in cisplatin-resistant ovarian cancer cells A2780cis both in vitro and in vivo.
Liu J; Zhang L; Zhang X; Xing X
J Chemother; 2015; 27(6):358-64. PubMed ID: 25976336
[TBL] [Abstract][Full Text] [Related]
3. The Impact of the Low Molecular Weight Heparin Tinzaparin on the Sensitization of Cisplatin-Resistant Ovarian Cancers-Preclinical In Vivo Evaluation in Xenograft Tumor Models.
Mueller T; Pfankuchen DB; Wantoch von Rekowski K; Schlesinger M; Reipsch F; Bendas G
Molecules; 2017 May; 22(5):. PubMed ID: 28467373
[TBL] [Abstract][Full Text] [Related]
4. Reprogramming of glutamine metabolism via glutamine synthetase silencing induces cisplatin resistance in A2780 ovarian cancer cells.
Guo J; Satoh K; Tabata S; Mori M; Tomita M; Soga T
BMC Cancer; 2021 Feb; 21(1):174. PubMed ID: 33596851
[TBL] [Abstract][Full Text] [Related]
5. Overcome of Cisplatin Resistance in Ovarian Cancer by Combination of Low-intensity Ultrasound and Cisplatin.
Kip B; Aydin O
Curr Drug Deliv; 2023; 20(9):1380-1390. PubMed ID: 35761504
[TBL] [Abstract][Full Text] [Related]
6. Sanguinarine enhances cisplatin sensitivity via glutathione depletion in cisplatin-resistant ovarian cancer (A2780) cells.
Sarkhosh-Inanlou R; Molaparast M; Mohammadzadeh A; Shafiei-Irannejad V
Chem Biol Drug Des; 2020 Feb; 95(2):215-223. PubMed ID: 31512406
[TBL] [Abstract][Full Text] [Related]
7. Oridonin effectively reverses cisplatin drug resistance in human ovarian cancer cells via induction of cell apoptosis and inhibition of matrix metalloproteinase expression.
Ma S; Tan W; Du B; Liu W; Li W; Che D; Zhang G
Mol Med Rep; 2016 Apr; 13(4):3342-8. PubMed ID: 26935490
[TBL] [Abstract][Full Text] [Related]
8. A biscarbene gold(I)-NHC-complex overcomes cisplatin-resistance in A2780 and W1 ovarian cancer cells highlighting pERK as regulator of apoptosis.
König P; Zhulenko R; Suparman E; Hoffmeister H; Bückreiß N; Ott I; Bendas G
Cancer Chemother Pharmacol; 2023 Jul; 92(1):57-69. PubMed ID: 37272932
[TBL] [Abstract][Full Text] [Related]
9. High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro.
Kozubík A; Horváth V; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Zák F; Mistr A; Turánek J
Biochem Pharmacol; 2005 Feb; 69(3):373-83. PubMed ID: 15652229
[TBL] [Abstract][Full Text] [Related]
10. Hsp90 inhibitor geldanamycin increases the sensitivity of resistant ovarian adenocarcinoma cell line A2780cis to cisplatin.
Solár P; Horváth V; Kleban J; Koval' J; Solárová Z; Kozubík A; Fedorocko P
Neoplasma; 2007; 54(2):127-30. PubMed ID: 17319785
[TBL] [Abstract][Full Text] [Related]
11. Susceptibility of CD24(+) ovarian cancer cells to anti-cancer drugs and natural killer cells.
Koh J; Lee SB; Park H; Lee HJ; Cho NH; Kim J
Biochem Biophys Res Commun; 2012 Oct; 427(2):373-8. PubMed ID: 22995296
[TBL] [Abstract][Full Text] [Related]
12. Immune escape of AKT overexpressing ovarian cancer cells.
Hahne JC; Meyer SR; Gambaryan S; Walter U; Dietl J; Engel JB; Honig A
Int J Oncol; 2013 May; 42(5):1630-5. PubMed ID: 23467686
[TBL] [Abstract][Full Text] [Related]
13. Oxaliplatin regulates expression of stress ligands in ovarian cancer cells and modulates their susceptibility to natural killer cell-mediated cytotoxicity.
Siew YY; Neo SY; Yew HC; Lim SW; Ng YC; Lew SM; Seetoh WG; Seow SV; Koh HL
Int Immunol; 2015 Dec; 27(12):621-32. PubMed ID: 26138671
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin-mediated down-regulation of miR-145 contributes to up-regulation of PD-L1 via the c-Myc transcription factor in cisplatin-resistant ovarian carcinoma cells.
Sheng Q; Zhang Y; Wang Z; Ding J; Song Y; Zhao W
Clin Exp Immunol; 2020 Apr; 200(1):45-52. PubMed ID: 31821542
[TBL] [Abstract][Full Text] [Related]
15. Knockdown of platinum-induced growth differentiation factor 15 abrogates p27-mediated tumor growth delay in the chemoresistant ovarian cancer model A2780cis.
Meier JC; Haendler B; Seidel H; Groth P; Adams R; Ziegelbauer K; Kreft B; Beckmann G; Sommer A; Kopitz C
Cancer Med; 2015 Feb; 4(2):253-67. PubMed ID: 25490861
[TBL] [Abstract][Full Text] [Related]
16. Adenosine Analogues as Opposite Modulators of the Cisplatin Resistance of Ovarian Cancer Cells.
Bednarska-Szczepaniak K; Krzyżanowski D; Klink M; Nowak M
Anticancer Agents Med Chem; 2019; 19(4):473-486. PubMed ID: 30657045
[TBL] [Abstract][Full Text] [Related]
17. Salinomycin induces apoptosis via death receptor-5 up-regulation in cisplatin-resistant ovarian cancer cells.
Parajuli B; Shin SJ; Kwon SH; Cha SD; Chung R; Park WJ; Lee HG; Cho CH
Anticancer Res; 2013 Apr; 33(4):1457-62. PubMed ID: 23564786
[TBL] [Abstract][Full Text] [Related]
18. Pre-Treatment of platinum resistant ovarian cancer cells with an MMP-9/MMP-2 inhibitor prior to cisplatin enhances cytotoxicity as determined by high content screening.
Laios A; Mohamed BM; Kelly L; Flavin R; Finn S; McEvoy L; Gallagher M; Martin C; Sheils O; Ring M; Davies A; Lawson M; Gleeson N; D'Arcy T; d'Adhemar C; Norris L; Langhe R; Saadeh FA; O'Leary JJ; O'Toole SA
Int J Mol Sci; 2013 Jan; 14(1):2085-103. PubMed ID: 23340649
[TBL] [Abstract][Full Text] [Related]
19. The effect of sodium butyrate and cisplatin on expression of EMT markers.
Mrkvicova A; Chmelarova M; Peterova E; Havelek R; Baranova I; Kazimirova P; Rudolf E; Rezacova M
PLoS One; 2019; 14(1):e0210889. PubMed ID: 30653577
[TBL] [Abstract][Full Text] [Related]
20. Promotion of Cell Death in Cisplatin-Resistant Ovarian Cancer Cells through KDM1B-DCLRE1B Modulation.
Lee YK; Lim J; Yoon SY; Joo JC; Park SJ; Park YJ
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31108893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]